|Bid||4.6500 x 1000|
|Ask||4.9500 x 1400|
|Day's Range||4.5600 - 5.1650|
|52 Week Range||3.1000 - 9.4900|
|Beta (3Y Monthly)||4.42|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 27, 2019 - Apr 1, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||11.00|
Providence Cancer Institute and Galectin Therapeutics Inc. (GALT), the leading developer of therapeutics that target galectin proteins, announced today a presentation highlighting the improved response of T cells seen in combination immunotherapy for cancer using GR-MD-02, to be given at a workshop for Recent Advances in Drugging the Innate Immune Response, on Monday, March 25, at 15:00 MDT, at Grays Peak at the Keystone Symposia on Molecular and Cellular Biology in Keystone, Colorado. Elizabeth Sturgill, Ph.D., Postdoctoral Fellow in the laboratory of Associate Member William L. Redmond, Ph.D., at the Earle A. Chiles Research Institute in Portland, Oregon, a division of Providence Cancer Institute, will give an oral presentation entitled “Galectin-3 Inhibition with GR-MD-02 Synergizes with T Cell-Targeting Immunotherapy, Leading to Reduced Immune Suppression and Improved Overall Survival.” The session will focus on the effects GR-MD-02 has had when combined with various T-cell targeting immunotherapies, including both aOX40 and Pembrolizumab (KEYTRUDA®).
It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes to zero. But if you buy sharesRead More...
As you may know, I have been on the board for slightly over a year and Chairman since May 2018. While my message relates primarily to the Company’s Rights Offering that was announced today, I also thought it was important to share some of my other thoughts about the Company. Before I speak about anything else, I would like to categorically state that I believe in free market capitalism and its inherent power to improve and save lives. No other system has proven to possess this ability, and in fact other systems tend to yield the opposite result. My belief in the power of free market capitalism extends from technical innovation to transparency in most aspects of society. I intend to cover both aspects as they relate to Galectin Therapeutics.
Galectin Therapeutics Inc. (GALT), the leading developer of therapeutics that target galectin proteins, today filed a Registration Statement on Form S-3 with the U.S. Securities and Exchange Commission (“SEC”) (available at www.sec.gov) with regards to a planned Rights Offering of common stock and warrants to its stockholders. In the Rights Offering the Company will seek to raise between $50 million and $70 million. Richard E. Uihlein, chairman of the board, has indicated his non-binding intent to purchase $20 million in the offering.
Galectin Therapeutics Inc. (GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results for the year ended December 31, 2018. Harold H. Shlevin, Ph.D., President and Chief Executive Officer of Galectin Therapeutics, said, “Over the last year we have been positioning the company to undertake a Phase 3 clinical trial -- the NASH-RX trial -- with our proprietary compound GR-MD-02, the first drug to show positive results in a clinical trial in patients with compensated NASH cirrhosis without esophageal varices.
NEW YORK, Feb. 26, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
NORCROSS, Ga., Feb. 25, 2019 -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold.
Conatus (CNAT) completes enrollment in a phase IIb study on emricasan, being developed for the treatment of patients with fibrosis or cirrhosis caused by NASH.
Ascendis Pharma (ASND) submits regulatory application to initiate a phase II study in the United States on its hypoparathyroidism therapy candidate, TransCon PTH.
Alkermes (ALKS) falls almost 5% on a Complete Response Letter from the FDA for its pipeline candidate, ALKS 5461for major depressive disorder (MDD).
AVEO Oncology (AVEO) decides against filing NDA for Fotivda on recommendation of the FDA. The agency remains concerned with the overall survival data.
Galectin Therapeutics Inc. (GALT), the leading developer of therapeutics that target galectin proteins, today announced that its largest institutional shareholder, 10X Fund L.P., has converted all of its Series B Convertible Preferred Stock into Common Stock of Galectin Therapeutics. All special voting rights and protective provisions that previously benefited the Series B Preferred Stock were extinguished by the conversion to Common Stock (see footnote 5 of our financial statements included in our Annual Report on Form 10-K for 2017 for all of the now extinguished special voting rights and protective provisions).
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. Unfortunately, there are also plenty of examples of share prices Read More...
NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Investors need to pay close attention to Galectin Therapeutics (GALT) stock based on the movements in the options market lately.
NORCROSS, Ga., Nov. 05, 2018 -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that an abstract.
The stars are aligning for several biotech stocks. Most often occurring in obese or glucose-intolerant people, Nonalcoholic Steatohepatitis or NASH is quickly increasing in prevalence. For those nations with fatty diets, the prevalence of NASH are estimated to be as much as 20% of the total population.
Galectin Therapeutics (GALT) posts favorable results from a phase Ib study on GR-MD-02 combined with Merck's Keytruda for treating metastatic melanoma.